Semax and Neuroprotection Research: ACTH Analogue Biology, BDNF Modulation and Ischaemic Brain Injury Mechanisms UK 2026

This article is intended for researchers and laboratory professionals. All peptides discussed are for research use only (RUO) and are not approved for human administration, therapeutic use, or clinical application. PeptidesLab UK supplies research-grade Semax for in vitro and in vivo laboratory investigations only.

Semax Biology: ACTH(4-7)PGP Pharmacology and Neuroprotective Mechanisms

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, 7 amino acids, MW 887 Da) is a synthetic heptapeptide derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH) with a Pro-Gly-Pro (PGP) C-terminal extension that confers resistance to enzymatic degradation. Unlike ACTH itself, Semax lacks the full ACTH sequence required for MC2R (ACTH receptor) activation and does not stimulate corticosteroid production — its biological effects are mediated through a distinct, incompletely characterised receptor profile involving MC4R partial agonism, BDNF/TrkB pathway upregulation, and direct modulation of the neurotrophin system. For neuroprotection research, Semax is particularly valuable as a tool for investigating BDNF-mediated neuroprotection mechanisms, ischaemic stroke recovery, and cognitive enhancement biology without the endocrine confounds of full ACTH administration.

Semax’s stability profile distinguishes it from native ACTH(4-10): PGP extension C-terminal protection prevents carboxypeptidase cleavage; Met-Glu-His N-terminal sequence is resistant to aminopeptidase attack at physiological concentrations. Intranasal administration routes (olfactory-trigeminal pathway to CNS) achieve peak brain concentrations within 20-30 min with 30-60 min duration of measurable neurotrophin effects — enabling within-animal baseline-controlled experimental designs in neuroscience research.

BDNF Upregulation: Semax-TrkB Axis and Neuroprotective Signalling

Brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB (tropomyosin receptor kinase B) represent the primary molecular mechanism through which Semax exerts neuroprotective and neuroplastic effects. Research demonstrates that Semax (0.1-1 mg/kg i.n. or i.p.) significantly elevates hippocampal, cortical, and striatal BDNF mRNA (RT-qPCR, Taqman Rn02531967_s1 for rat, Mm04230607_s1 for mouse) and protein (ELISA, Promega G7611 two-site ELISA, fg/mg tissue) within 1-6 hours post-administration, with peak elevation at 2-3h and return to baseline by 12-24h. The mechanism of BDNF transcriptional induction involves CREB Ser-133 phosphorylation (via cAMP-PKA signalling downstream of putative MC4R partial agonism) activating the CaRE/CRE element in BDNF promoter IV (the primary activity-dependent BDNF promoter, quantified by ChIP with anti-pCREB Ser-133, Cell Signaling 9198).

TrkB activation downstream of Semax-induced BDNF: auto-phosphorylation at Tyr-706/707 (kinase domain activation) and Tyr-816 (PLCγ1 docking) assessed by western (anti-pTrkB Tyr-816, Cell Signaling 4168) in hippocampal lysates 30-120 min post-BDNF induction peak. Downstream TrkB-PI3K-Akt Ser-473 (survival pathway), TrkB-Ras-MAPK-ERK1/2 Thr-202/Tyr-204 (plasticity pathway), and TrkB-PLCγ1 Tyr-783-IP₃-Ca²⁺-CaMKII Thr-286 (synaptic pathway) provide the mechanistic framework. TrkB antagonist K252a (200 nM intracerebroventricular, 10 min before Semax) or ANA-12 (anti-TrkB, 0.5 mg/kg i.p.) confirms TrkB-dependence of neuroprotective endpoints in ischaemia models. Pro-BDNF versus mature BDNF discrimination by ELISA (using N-terminal pro-domain antibody versus mature BDNF antibody) is important since pro-BDNF activates p75NTR → apoptosis, opposing mature BDNF-TrkB survival signalling.

Ischaemic Stroke Models: MCAO and Global Ischaemia Research

The middle cerebral artery occlusion (MCAO) model is the gold-standard focal cerebral ischaemia model for Semax neuroprotection research. In adult male Sprague-Dawley rats (280-320g) or C57BL/6 mice (20-25g): intraluminal suture MCAO (4-0 nylon monofilament, silicon-coated tip 0.35 mm round, inserted via external carotid artery to MCA origin, confirmed by laser Doppler flowmetry ≥75% flow reduction); 90-min transient occlusion (tMCAO) → reperfusion; Semax treatment at reperfusion onset (0.1-1 mg/kg i.n. or i.p.) or 6h post-onset (delayed therapeutic window). Primary endpoints: (i) infarct volume at 24h (TTC staining, 2 mm coronal sections, 1% TTC 37°C 30 min, image analysis, % contralateral hemisphere × volume mm³); (ii) neurological deficit score (modified Bederson, 0-4; or Garcia, 0-18); (iii) TUNEL+ neurons in penumbra (3 cortical sections × 3 fields, cells/mm²) versus core; (iv) activated caspase-3 IHC (anti-cleaved caspase-3, Cell Signaling 9661).

Penumbra-specific research: the ischaemic penumbra (electrically silent but metabolically viable tissue surrounding the necrotic core) is the primary therapeutic target. Perfusion-diffusion mismatch by MRI (7T small animal scanner, DWI-PWI, 90 min post-MCAO) defines the penumbra volume; Semax effects on converting penumbra to surviving tissue (saved penumbra volume = MRI penumbra − TTC infarct at 24h) provide the translational efficacy metric. Protein synthesis recovery (14C-leucine autoradiography at 2h, 6h, 24h), ATP content (luciferin-luciferase bioluminescence), and pH (phosphorus MRS) in penumbral tissue characterise the metabolic rescue achieved by Semax.

Inflammatory Cascade Modulation: Microglia, NF-κB, and Cytokine Research

Post-ischaemic neuroinflammation involves microglial M1 activation (pro-inflammatory, NF-κB-driven) that amplifies ischaemic injury in the 24-72h reperfusion period. Semax modulates this inflammatory cascade through BDNF-TrkB anti-inflammatory signalling and putative MC4R-Gs-cAMP-PKA-CREB axis suppression of NF-κB. Research endpoints: (i) Iba-1 IHC (microglial activation marker, WAKO 019-19741) and CD68 IHC (phagocytic activated microglia, Abcam ab31630) in perinfarctal cortex at 24h, 72h, 7d — BioImageXD morphological analysis (process length, branch number, cell body area); (ii) NF-κB p65 nuclear western and IHC in periinfarct cortex; (iii) Luminex 7-plex (TNF-α, IL-1β, IL-6, IL-10, CXCL1, MCP-1, IFN-γ) in cortical homogenate and plasma at 24h and 72h post-MCAO ± Semax; (iv) reactive oxygen species (DHE in vivo dihydroethidium i.p. 30 min before sacrifice, frozen sections, confocal 585 nm oxidised DHE fluorescence, cells/mm²); (v) matrix metalloproteinases MMP-2 and MMP-9 zymography in brain lysate — relevant to blood-brain barrier disruption and oedema formation.

Primary microglia research: isolated microglia (adult rat cortex, percoll 30/70% gradient, CD11b MACS positive selection, ≥92% Iba-1+ purity) stimulated with LPS (100 ng/mL, 4h prime) + ATP (1 mM, 30 min, NLRP3 activation second signal) ± Semax (10-1000 nM pre-treatment 30 min). Luminex TNF-α-IL-1β-IL-6-IL-10, NLRP3 western, caspase-1 p10 processing, and NF-κB p65 EMSA define Semax’s anti-inflammatory profile in isolated microglia — separating direct cellular effects from indirect BDNF-mediated effects observable only in neuron-glia co-cultures.

Cognitive and Memory Research: Spatial Learning and Synaptic Plasticity

Beyond acute neuroprotection, Semax’s BDNF-upregulating properties position it as a research tool in cognitive neuroscience. Spatial learning and memory paradigms used with Semax include: (i) Morris Water Maze (MWM) — hidden platform 4-day training (2 trials/day, 60 s maximum, 180 s inter-trial interval), probe trial day 5 (60 s, platform removed, % time in target quadrant, platform zone crossings), and visible platform day 6 (sensorimotor control, no hidden platform); (ii) Novel Object Recognition (NOR) — 10 min habituation, 10 min training with two identical objects, 24h delay test with one novel object replaced, discrimination index (DI = (tn-tf)/(tn+tf) > 0.5 = memory); (iii) Fear Conditioning — contextual (CFC, 24h test, % freezing in training context) and cued (tone CS, 48h test in novel context); (iv) Barnes Maze — less stressful alternative to MWM, 20 holes, 4-day training, probe trial.

Synaptic plasticity research: hippocampal long-term potentiation (LTP) in acute hippocampal slices (450 μm transverse, Schaffer collateral-CA1 pathway, 0.1 Hz baseline test pulses, TBS theta-burst stimulation 10 bursts × 4 pulses × 100 Hz at 200 ms burst interval). LTP magnitude measured as % potentiation of field EPSP slope 60 min post-TBS. Semax (100-1000 nM bath application 20 min before TBS) enhances LTP expression in an ANA-12-sensitive (TrkB-dependent) manner. GluN2B (NR2B) Tyr-1472 phosphorylation (western, anti-pNR2B Tyr-1472, Cell Signaling 4208) and GluA1 (AMPA subunit) Ser-831/Ser-845 phosphorylation (PKC/CaMKII and PKA-dependent respectively) quantify the synaptic molecular correlates of plasticity enhancement.

Blood-Brain Barrier and Intranasal Delivery Research

Semax is typically administered intranasally in research (olfactory-trigeminal route bypassing BBB) or systemically (i.p., i.v. with CNS penetration via active transport or paracellular diffusion). BBB penetration research: [³H]-Semax or Alexa-647-labelled Semax administered intranasally (10 μL per nare, μL micropipette under light isoflurane, head tilted back) or i.v., brains perfused at 20, 40, 60 min (saline perfusion 100 mL transcardially to clear intravascular peptide), homogenised, scintillation counting for [³H] or confocal for fluorescent label, expressed as %ID/g brain tissue. Olfactory bulb shows highest concentrations (30-40 min), followed by cortex and hippocampus (60-90 min), establishing the pharmacokinetic profile for intranasal CNS delivery.

BBB integrity research in ischaemic models: Evans Blue dye (2% in saline, 4 mL/kg i.v., 2h before sacrifice, spectrophotometry of formamide brain extract at 620 nm) quantifies BBB permeability. Tight junction protein expression (ZO-1, occludin, claudin-5) by western in cortical microvascular fraction (isolated by dextran sedimentation and centrifugation) at 24h post-MCAO ± Semax. MMP-9 zymography in peri-infarct cortex and CSF — MMP-9-mediated laminin and collagen IV degradation of basement membrane is the primary mechanism of BBB opening in the 6-24h post-ischaemic window; Semax-BDNF-TrkB-mediated suppression of MMP-9 provides mechanistic protection against BBB disruption and secondary haemorrhagic transformation.

Oxidative Stress and Mitochondrial Protection Research

Ischaemia-reperfusion injury generates massive oxidative burst through xanthine oxidase, NADPH oxidase, uncoupled mitochondrial ETC, and NOS uncoupling. Semax neuroprotection research addresses the antioxidant component through NRF2 (nuclear factor erythroid 2-related factor 2) pathway activation — the master antioxidant transcriptional regulator. Semax (1 mg/kg i.n.) increases nuclear NRF2 (anti-NRF2, Abcam ab62352, nuclear fractionation western) and downstream antioxidant gene expression: HO-1 (haeme oxygenase 1), NQO1 (NAD(P)H quinone oxidoreductase 1), and GCLC (glutamate-cysteine ligase catalytic subunit) mRNA by qPCR at 6h post-treatment. GSH/GSSG ratio (Promega GSH/GSSG-Glo), SOD activity (SOD Assay Kit, Sigma 19160), and catalase activity (Sigma CAT-100) in cortical homogenate at 24h post-MCAO provide the oxidative stress resolution readout.

Mitochondrial protection: isolated cortical mitochondria (differential centrifugation, Percoll 40/23% gradient purification, JC-1 membrane potential ΔΨm at 530/590 nm ratio, Seahorse XFe96 oxygen consumption rate OCR — state 3 ADP-stimulated, state 4 oligomycin, FCCP uncoupled maximal, respiratory control ratio RCR = state 3:state 4) in mitochondria isolated from Semax-treated versus vehicle MCAO animals at 2h reperfusion, when ischaemia-induced mitochondrial dysfunction is at its maximum. Cytochrome c release (ELISA in cytosolic fraction of cortical lysate, R&D DCTC0) and mPTP (mitochondrial permeability transition pore) opening (calcein-AM+CoCl₂ assay, flow cytometry — CoCl₂ quenches cytosolic calcein, mitochondrial calcein retention as % of control) complete the mitochondrial protection panel.

Control Design and Research Rigour

Rigorous Semax neuroprotection research requires: (i) MC4R specificity — SHU9119 (MC3R/MC4R antagonist, 1 mg/kg i.p.) or HS131 (MC4R-selective, 3 mg/kg i.p.) before Semax to confirm melanocortin receptor contributions; (ii) TrkB-dependence — ANA-12 or K252a pharmacological TrkB blockade; (iii) BDNF knockout validation — BDNF heterozygous mice (BDNF⁺/⁻, B6.129P2-Bdnf/J) showing partial attenuation of Semax neuroprotection; (iv) MCAO technical validation — laser Doppler flowmetry ≥75% reduction at occlusion, recovery >80% at reperfusion onset confirming model fidelity; (v) blinding — infarct volume measurement, neurological scoring, and immunohistological quantification by observer blinded to treatment group; (vi) sex stratification — female ischaemia outcomes differ from male (protective progesterone and oestrogen effects) requiring sex-stratified cohorts; (vii) peptide quality — ≥98% HPLC, MW 887 Da mass confirmed, endotoxin ≤1 EU/mg; (viii) physiological monitoring — body temperature (rectal probe, maintained 37.0±0.5°C via heating pad), blood gases (PaO₂, PaCO₂, pH from femoral artery catheter) during MCAO confirming respiratory and thermal equivalence across groups.